A randomized prospective trial of amphotericin B lipid emulsion versus dextrose colloidal solution in critically ill patients

Journal of Trauma - Injury, Infection and Critical Care

Volumn 47, Issue 2, 1999, Pages 336-340

  Barquist, Erik ^a,b   Fein, Eleanor ^a   Shadick, David ^a   Johnson, Joseph ^a   Clark, John ^a   Shatz, David ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Amphotericin B; Critical illness; Fungal infections; Fungemia; Nephrotoxicity; Sepsis

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; INTRALIPID; VANCOMYCIN;

ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA TROPICALIS; CANDIDIASIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLLOID; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; CRITICAL ILLNESS; DRUG MIXTURE; DRUG SAFETY; EMULSION; FUNGEMIA; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC MYCOSIS;

EID: 0032811743     PISSN: 00225282     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005373-199908000-00020     Document Type: Article

References (24)

1. Beck-Sague CM, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis. 1993;167:1247-1251.
2. Sawaya BP, Briggs JP, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequences of altered membrane properties. J Am Soc Nephrol. 1995;6:154-164.
3. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis. 1990; 12: 308-329.
4. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of Amphotericin B: clinical efficacy and toxicities. Clin Infect Dis. 1998;27:603-618.
5. Fujisawa USA, Inc. AmBisome (amphotericin B) liposome for injection product label. Deerfield, Ill: Fujisawa Healthcare; 1998
6. Kirsh R, Goldstein R, Tarloff J, et al. An emulsion formulation of AmB improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis. 1988; 158:1065-1070.
7. Patterson TF, Miniter P, Dijkstra J, et al. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis. 1989;159: 717-724.
8. Leake HA, Appleyard MN, Hartley JP. Successful treatment of resistant cryptococcal meningitis with amphotericin B lipid emulsion after nephrotoxicity with conventional intravenous amphotericin B. J Infect. 1994;28:319-322.
9. Moreau P, Milpied N, Fayette N, et al. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with Intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother. 1992;30:535-541.
10. Caillot D, Reny G, Solary E, et al. A controlled trial of the tolerance of Amphotericin B infused in dextrose or in intralipid in patients with haematological malignancies. J Antimicrob Chemother. 1994;33:603-613.
11. Sorkine P, Nagar H, Weinbroum A, et al. Administration of amphotericin B in lipid emulsion decreases nephrotoxicity: results of a prospective, randomized, controlled study in critically ill patients. Crit Care Med. 1996;24:1311-1315.
12. Zager RA, O'Quigley J, Zager BK, et al. Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis. 1989;13:210-216.
13. Butler WT, Bennett JE, Alling DW, et al. Nephrotoxicity of amphotericin B: early and late effects in 81 patients. Ann Intern Med. 1964;61:175-187.
14. Sabra R, Branch RA. Amphotericin B nephrotoxicity. Drug Saf. 1990;5:94-108.
15. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis. 1992;11:99-109.
16. Kaloyanides GJ. Antibiotic related nephrotoxicity. Nephrol Dial Transplant. 1994;9:130-134.
17. Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int. 1991;40:302-308.
18. Trissel LA. Amphotericin B does not mix with fat emulsion. Am J Health Syst Pharm. 1995;52:1463-1464.
19. Ericsson O. Amphotericin B is incompatible with lipid emulsions. Ann Pharmacother. 1996;30:298.
20. Cleary JD. Amphotericin B formulated in a lipid emulsion. Ann Pharmacother. 1996;30:409-412.
21. Ranchere JY, Latour JF, Fuhrmann C, et al. Amphotericin B intralipid formulation: stability and particle size. J Antimicrob Chemother. 1996;37:1165-9.
22. Lopez RM, Ayestaran A, Pou L, et al. Stability of amphotericin B in an extemporaneously prepared i.v. fat emulsion. Am J Health Syst Pharm. 1996;53:2724-2727.
23. Shadkhan Y, Segal E, Bor A. The use of commercially available lipid emulsions of the preparation of amphotericin B-lipid admixtures. J Antimicrob Chemother. 1997;39: 655-658.
24. Schoffski P, Freund M, Wunder R, et al. Safety and toxicity of amphotericin B in glucose 5% or intralipid 20% in neutropenic patients with pneumonia or fever of unknown origin: randomised study. BMJ. 1998;317:379-384.